Prognosis of grade 3-4 acute GVHD continues to be dismal

Bone Marrow Transplantation

Volumn 48, Issue 10, 2013, Pages 1359-1361

  Jamani, K ^a   Russell, J A ^a   Daly, A ^a   Stewart, D ^a   Savoie, L ^a   Duggan, P ^a   Storek, J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; FLUDARABINE; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CAUSE OF DEATH; CHEMOPROPHYLAXIS; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE CLASSIFICATION; FOLLOW UP; HUMAN; LETTER; LONG TERM SURVIVAL; MORTALITY; MYCOSIS; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS INFECTION;

ACUTE DISEASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PROGNOSIS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

EID: 84885634879     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.59     Document Type: Letter

References (9)

1. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091-2101.
2. Pond GR, Lipton JH, Messner HA. Long-term survival after blood and marrow transplantation: comparison with an age-and gender-matched normative population. Biol Blood Marrow Transplant 2006; 12: 422-429. (Pubitemid 43380959)
3. MacMillan ML, Weisdorf DJ, Davies SM, DeFor TE, Burns LJ, Ramsay NK et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2002; 8: 40-46. (Pubitemid 34141550)
4. Saliba RM, Couriel DR, Giralt S, Rondon G, Okoroji GJ, Rashid A et al. Prognostic value of response after upfront therapy for acute GVHD. Bone Marrow Transplant 2012; 47: 125-131.
5. Champlin RE, Perez WS, Passweg JR, Klein JP, Camitta BM, Gluckman E et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood 2007; 109: 4582-4585. (Pubitemid 46743430)
6. Doney KC, Weiden PL, Storb R, Thomas ED. Failure of early administration of antithymocyte globulin to lessen graft-versus-host disease in human allogeneic marrow transplant recipients. Transplantation 1981; 31: 141-143. (Pubitemid 11176778)
7. Dietrich S, Falk CS, Benner A, Karamustafa S, Hahn E, Andrulis M et al. Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. Biol Blood Marrow Transplant 2013; 19: 22-27.
8. Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 2005; 366: 733-741. (Pubitemid 41207235)
9. Bacigalupo A, Lamparelli T, Milone G, Sormani MP, Ciceri F, Peccatori J et al. Preemptive treatment of acute GVHD: a randomized multicenter trial of rabbit antithymocyte globulin, given on day7 after alternative donor transplants. Bone Marrow Transplant 2010; 45: 385-391.